Claims for Patent: 8,404,717

Summary for Patent: 8,404,717

Title:	Methods of treating myelodysplastic syndromes using lenalidomide
Abstract:	Methods of treating, preventing and/or managing myelodysplastic syndromes are disclosed. Specific methods encompass the administrations of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin-2,6-dione in combination with 5-azacytidine.
Inventor(s):	Zeldis; Jerome B. (Princeton, NJ)
Assignee:	Celgene Corporation (Summit, NJ)
Application Number:	13/070,761
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,404,717
Patent Claims:	1. A method of treating a patient having transfusion dependent anemia due to low to intermediate-1-risk myelodysplastic syndrome, which comprises administering to said patient in need thereof about 5 to about 25 mg per day of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione having the formula: ##STR00010## or a pharmaceutically acceptable salt, solvate or stereoisomer thereof. 2. The method of claim 1, wherein the compound is administered in the amount of 5 mg per day. 3. The method of claim 2, wherein the compound is administered orally in an amount of 5 mg as a capsule per day. 4. The method of claim 1, wherein the compound is administered in the amount of 10 mg per day. 5. The method of claim 4, wherein the compound is administered orally in an amount of 10 mg as a capsule per day. 6. The method of claim 1, wherein the compound is administered in the amount of 15 mg per day. 7. The method of claim 6, wherein the compound is administered orally in an amount of 15 mg as a capsule per day. 8. The method of claim 1, wherein the compound is administered in the amount of 25 mg per day. 9. The method of claim 8, wherein the compound is administered orally in an amount of 25 mg as a capsule per day. 10. The method of claim 3, 5, 7 or 9, wherein the compound 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione is as a free base.